Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 5/20 | 0.44 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16894268 | 0.85 | KIF11 (0.56) | CYP11B1CYP11B2ALOX5APFEN1AR | |
| SCHEMBL495426 | 0.83 | CYP11B1 (0.57) | TRPV4CYP11B1CYP11B2ALOX5APFEN1 | |
| SCHEMBL29546917 | 0.83 | AR (0.52) | CYP11B1CYP11B2ARKIF11PTPN1 | |
| SCHEMBL12151755 | 0.83 | AR (0.52) | CYP11B1CYP11B2ARKIF11PTPN1 | |
| SCHEMBL11684021 | 0.82 | TRPV4 (0.39) | TRPV4CYP11B1CYP11B2ALOX5APFEN1 | |
| SCHEMBL1104684 | 0.82 | KIF11 (0.42) | TRPV4ALOX5APARKIF11NR3C1 | |
| SCHEMBL25658474 | 0.81 | ALOX5AP (0.50) | TRPV4CYP11B1CYP11B2ALOX5APFEN1 | |
| SCHEMBL23901085 | 0.80 | NR3C1 (0.40) | TRPV4CYP11B1CYP11B2ALOX5APFEN1 | |
| SCHEMBL31391676 | 0.80 | NR3C1 (0.40) | TRPV4CYP11B1CYP11B2ALOX5APFEN1 | |
| SCHEMBL25658482 | 0.80 | ALOX5AP (0.49) | TRPV4CYP11B1CYP11B2ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| EP-3802500-B1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12492181-B2 | Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| US-12479828-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12479825-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12466829-B2 | Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2025-10-07 | — | — | US | disclosed |
| US-20250243169-A1 | PROCESS FOR THE PREPARATION OF DIVERSELY SUBSTITUTED CYANOCYCLOPROPYL-HETEROCYCLES OR ARENES | SYNGENTA CROP PROTECTION AG (CH) | 2025-07-31 | — | — | US | disclosed |
| EP-4574822-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | Kamari Pharma Ltd. (IL) | 2025-06-25 | — | — | EP | disclosed |
| EP-4504706-A1 | PROCESS FOR THE PREPARATION OF DIVERSELY SUBSTITUTED CYANOCYCLOPROPYL - HETEROARENES OR ARENES | Syngenta Crop Protection AG (CH) | 2025-02-12 | — | — | EP | disclosed |
| US-5489592-A | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF DIABETES-RELATED DISORDERS | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1996-02-06 | — | — | US | disclosed |
| EP-0442655-B1 | Benzisoxazole derivatives | ZENECA LTD (GB) | 1996-01-17 | — | — | EP | disclosed |
| EP-0607344-A1 | 3,4-DIHYDRO-4-OXO-3-(PROP-2-ENYL)-1-PHTALAZINEACETIC ACIDS AND DERIVATIVES, PREPARATIONS THEREOF AND DRUGS CONTAINING SAME | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993007109-A1 | 3,4-DIHYDRO-4-OXO-3-(PROP-2-ENYL)-1-PHTALAZINEACETIC ACIDS AND DERIVATIVES, PREPARATIONS THEREOF AND DRUGS CONTAINING SAME | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1993-04-15 | — | — | WO | disclosed |
| US-5187176-A | 1-PHENYL SUBSTITUTED PYRIMIDONE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-16 | — | — | US | disclosed |
| US-5176737-A | BENZISOXAZOLE COMPOUNDS USEFUL AS HERBICIDES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-01-05 | — | — | US | disclosed |
| US-5109004-A | Cyano phenyl-substituted with heterocylic compound; insecticides, miticides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-04-28 | — | — | US | disclosed |
| CN-1054064-A | Heterogeneous ring compound | ICI PLC (GB) | 1991-08-28 | — | — | CN | disclosed |
| EP-0442655-A2 | Benzisoxazole derivatives | ZENECA LIMITED (GB) | 1991-08-21 | — | — | EP | disclosed |
| EP-0398499-A2 | Insecticides | ZENECA LIMITED (GB) | 1990-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | TRPV4 1346/4885CYP11B1 796/4885CYP11B2 786/4885 |
| US-12466829-B2 | Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC2R, MC1R, MC3R | TRPV4 221/4885CYP11B1 546/4885CYP11B2 265/4885 |
| US-20250243169-A1 | PROCESS FOR THE PREPARATION OF DIVERSELY SUBSTITUTED CYANOCYCLOPROPYL-HETEROCYCLES OR ARENES | CYCS, CCNE1, CCNT1 | TRPV4 4480/4885CYP11B1 54/4885CYP11B2 72/4885 |
| US-12479825-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | TRPV4 497/4885CYP11B1 390/4885CYP11B2 144/4885 |
| US-12492181-B2 | Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC1R, MC3R, MC2R | TRPV4 507/4885CYP11B1 1140/4885CYP11B2 541/4885 |
| US-12479828-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | TRPV4 497/4885CYP11B1 390/4885CYP11B2 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.